Atara Biotherapeutics vs Monte Rosa Therapeutics
Monte Rosa Therapeutics reported revenue of $124 million in fiscal 2025, about the same as Atara Biotherapeutics' $121 million in fiscal 2025. Atara Biotherapeutics' revenue fell 6.3% in its latest year, and Monte Rosa Therapeutics' grew 63.5%. Atara Biotherapeutics had an operating margin of 29.7%, against -43.8% at Monte Rosa Therapeutics. Free cash flow was −$51 million at Atara Biotherapeutics and −$28 million at Monte Rosa Therapeutics.
Side by side
| Atara Biotherapeutics | Monte Rosa Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $121M | $124M |
| Revenue growth | −6.3% | 63.5% |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | — | — |
| Operating margin | 29.7% | −43.8% |
| Net margin | 27.1% | −31.2% |
| Free cash flow | −$51M | −$28M |
| Free cash flow margin | −42.2% | −22.2% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 69.8% | 12.4% |
| Last close | $6.34 | $8.91 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $5.7 million, sold $3.8 million | sold $4.0 million |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Atara BiotherapeuticsMonte Rosa Therapeutics
Operating margin
Percent of revenue
Atara BiotherapeuticsMonte Rosa Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Atara BiotherapeuticsMonte Rosa Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Atara Biotherapeutics and Monte Rosa Therapeutics pages.